ABSTRACT:
ABSTRACT:
The anti-fungal nail lacquer which is used in treatment of onychomycosis skin fungal disorder was focus on the disease caused and treatment by nail lacquer, onychomycosis caused by the pathogens. The success of local topical therapy for onychomycosis depends on the achievement of effective chemical concentrations into/through the human nail plate; therefore, a suitable antifungal drug must be coupled with an appropriate delivery method. The formulations were prepared by simple mixing method and analyzed for gloss, smoothness to flow, drug diffusion studies, and % drug content. Among all formulations, nail lacquer prepared with 2% oxiconazole, 5% nitrocellulose, 0.75% ethyl cellulose, 20% salicylic acid, 10% propylene glycol and 10% 2-H ß-CD exhibited good drug release and drug content estimation i.e. F4 formulation. The drug release profiles were achieved 89.4% at 12 h. Nail lacquer was found to be stable after 1 month at 40±2?.
Cite this article:
Zaiba khanum. Development and Evaluation of Efinaconazole Containing Potential Permeation enhancer for an enhanced Transungual Drug Delivery. Asian Journal Research Chemistry.2026; 19(3):247-2. doi: 10.52711/0974-4150.2026.00038
Cite(Electronic):
Zaiba khanum. Development and Evaluation of Efinaconazole Containing Potential Permeation enhancer for an enhanced Transungual Drug Delivery. Asian Journal Research Chemistry.2026; 19(3):247-2. doi: 10.52711/0974-4150.2026.00038 Available on: https://ajrconline.org/AbstractView.aspx?PID=2026-19-3-10
REFERENCES:
1. Yadav K. A review on anti-fungal nail lacquer using treatment of onychomycosis. Int J Sci Res. 2019; 9(4): 352-57
2. Elkeeb R, Alikhan A, Elkeeb L. Transungual drug delivery: Current status. Int J Pharm. 2010; 384: 1–8.
3. Brown M, Traynor M. Treatment of fungal nail Infections. Drug delivery report spring/summer2007[internet]. Availablefrom: http://www.medpharm.co.uk/uploads/media/MedPharmFungalNailInfections.pdf.
4. Khan AD, Giri A, Singh L. Transungual drug delivery: a newer approach. World J Pharm Pharma Sci 2014; 3(3): 781-94.
5. Westerberg DP, Woyack MJ. Onychomycosis current trends in diagnosis and treatment. American Family Physician. 2013; 88(11): 762-70.
6. Wienberg JM, Koestenblatt EK, Tutrone WD, Tishler HR, Najarian L. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol. 2003; 49(2): 193-7.
7. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 1996; 23(2): 305-13.
8. Forslind B, Thyresson N. On the structure of the normal nail. Archiv Für Dermatologische Forschung. 1975; 1(3): 199-204.
9. Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. Drug permeation through the three layers of the human nail plate. J Pharma Pharmaco. 1999; 51(3): 271- 78.
10. Murthy SN, Zhao YL, Hui SW, Sen A. Electroporation and transcutaneous extraction (ETE) for pharmacokinetic studies of drugs. J Control Release. 2005; 105(1- 2): 132-41.
11. Shireesh KR, Chandra SB, Vishnu P, Prasad MVV. Ungual drug delivery systems of ketoconazole nail lacquer. Int J Appl Pharm. 2010; 2(4): 17-19.
12. Shivkumar HN, Vaka SR, Madhav NV, Chandra H, Murthy SN. Bilayered nail lacquer of terbinafine hydrochloride for treatment of onychomycosis. J Pharm Sci. 2010; 99(10): 4267-76.
13. Gupta AK, Lynde CW, Jain HC, Sibbald RG, Elewski BE, Daniel CR, Watteel GN, Summerbell RC. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicentre study. Br J Dermatol. 1997; 136(5): 786-89.
14. Kiran S, Shekar C. Ungual drug delivery system of ketoconazole nail lacquer. Asian J Pharm. 2010;1-3.
15. Metrin D, Lippold BC, In vitro permeability of the human nail and a keratin membrane from bovine hooves. J Pharm Pharmacol. 1997; 49(1): 30-34.